About

Precision radio­pharma­ceuticals

Precirix is a private biotechnology company dedicated to extending and improving the lives of cancer patients by designing and developing novel radiopharmaceuticals, using camelid-derived single-domain antibodies (sdAb) labeled with radioisotopes.

CAM-H2, a HER2-directed sdAb combined with iodine-131 recently completed a Phase I clinical study. The company’s Fibroblast Activation Protein (FAP)-targeting program is transitioning into the clinic.

The company’s technology platform allows for a theranostic approach, using the same molecule for patient selection (imaging) and therapy. In addition to CAM-FAP and CAM-H2, the company has product candidates in preclinical stage and is further broadening its platform through research on isotopes, linker technology and combination therapies.

History

2014
Camel-IDS incorporation
EUR 1M grant
2015
Seed financing
EUR 1M grant
2016
Start FIH study
2017
Seed financing to EUR 3M
CEO joins company
2018
EUR 37M series A
Completion FIH study
2019
Preparation Phase I/II study
EUR 0.8M grant
2020
IND approval Phase I/II study
2021
First patients dosed in Phase I/II study
2022
EUR 80m Series B completed
2023
Completion CAM-H2 Phase I study
2024
Tom Plitz joins as CEO

Your browser is not supported. Update your browser for more security, speed and to make the most of this site.